Thousand Oaks, California, September 3, 2025
News Summary
Amgen has announced a $600 million investment to construct a new research and development facility in Thousand Oaks, California. Slated to begin construction in the third quarter of this year, the facility will focus on next-generation drug discovery and enhance collaboration among researchers. This investment is part of a broader trend in the pharmaceutical industry to increase domestic capabilities amid rising demand for biomanufacturing. Amgen’s strategic move aims to strengthen drug supply chains and support ongoing innovation in healthcare.
California—Amgen has announced plans to invest $600 million in a new research and development facility in Thousand Oaks, California, set to commence construction in the third quarter of this year. This significant investment aims to bring together researchers, engineers, and scientists to enhance the process of next-generation drug discovery.
The new R&D center is designed specifically for collaborative research and will not serve as a drug manufacturing facility. By centralizing its operations, Amgen seeks to provide its teams with advanced tools that will facilitate scientific breakthroughs. The company is keen to further enhance its local capabilities amidst ongoing strains in the supply chain and significant U.S. import tariffs.
Amgen, which is headquartered in Thousand Oaks, currently manages nearly 2 million square feet of biotech space in the Conejo Valley, located about 40 miles west of Los Angeles. The investment in the new facility is a response to the increasing demand for biomanufacturing, a sector that is projected to see a considerable surge. In fact, 15 major drug manufacturers have committed over $270 billion to projects in the U.S. for 2025, illustrating a 185% increase in biomanufacturing demand, as reported by the commercial real estate firm JLL.
In the first half of this year, Alexandria Real Estate Equities has added more than half a million square feet of lab space, indicating a strong market response to rising demand for biotech facilities. Amgen’s plans follow its earlier declarations of a $900 million expansion of its manufacturing site in Columbus, Ohio, and a $1 billion investment in establishing a second manufacturing hub in Holly Springs, North Carolina.
The regulatory landscape for drug manufacturing is shifting, with the U.S. Food and Drug Administration (FDA) introducing initiatives aimed at expediting the approval processes for new manufacturing sites. Additionally, the White House has set goals to reduce construction timelines for pharmaceutical facilities, which currently average up to 10 years. Amgen acknowledges that the Tax Cuts and Jobs Act of 2017 has played a crucial role in fueling these domestic investments and anticipates forthcoming legislation to further bolster growth in the sector.
Amgen’s expansion strategy aligns with a broader trend in the pharmaceutical industry, where companies like AstraZeneca, Eli Lilly, Sanofi, and Novartis have also announced substantial investments in the U.S. These activities reflect a growing policy focus on reshoring pharmaceutical production to reduce reliance on foreign manufacturing, addressing concerns about the U.S. healthcare system’s dependency on international supply chains.
Overall, Amgen’s $600 million investment signifies the company’s commitment to enhancing domestic research capabilities and strengthening drug supply chains in the United States, thereby supporting ongoing innovation in the healthcare industry.
FAQ
What is Amgen’s investment in the new facility?
Amgen plans to invest $600 million to construct a new research and development facility in Thousand Oaks, California.
When is the construction of the new facility set to begin?
Construction is expected to break ground in the third quarter of this year.
What is the focus of the new research and development center?
The facility will focus on next-generation drug discovery, enhancing collaboration among researchers, engineers, and scientists.
Is the new Amgen facility for drug manufacturing?
No, the new facility is not a drug manufacturing site; it is dedicated to research and development.
Key Features of Amgen’s Investment
| Feature | Details |
|---|---|
| Investment Amount | $600 million |
| Location | Thousand Oaks, California |
| Focus of Facility | Next-generation drug discovery and research collaboration |
| Construction Start | Third quarter of the year |
| Current Facilities in Conejo Valley | Nearly 2 million square feet |
| Impact on Biomanufacturing | Part of a $270 billion investment trend in the U.S. |
Deeper Dive: News & Info About This Topic
- Fierce Biotech: Amgen to Build $600M R&D Site
- Wikipedia: Amgen
- BioPharma Dive: Amgen’s New Research Center
- Google Search: Amgen investment in California
- CoStar: Amgen Extends Pharmaceutical Real Estate Push
- Encyclopedia Britannica: Amgen, Inc.
- Business Facilities: Amgen Plans $600M Center
- Google Scholar: Amgen R&D facility
- Reuters: Amgen to Expand Ohio Biotech Plant
- Google News: Biomanufacturing in the US
